Related Experiment Videos
Sexual function after permanent 125I-brachytherapy for prostate cancer.
1Department of Urology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. nicolam@tasmc.health.gov.il
International Journal of Impotence Research
|October 29, 2004
Summary
Permanent prostate brachytherapy (125I) temporarily impacts erectile function (EF), but recovery is expected within one year for most patients. Sexual function satisfaction remains high post-treatment.
Area of Science:
- Urology
- Oncology
- Sexual Medicine
Background:
- Localized prostate cancer treatment often involves radiation therapy.
- Permanent 125I-brachytherapy is a common treatment modality.
- Assessing post-treatment erectile function (EF) is crucial for patient quality of life.
Purpose of the Study:
- To prospectively evaluate erectile function (EF) after permanent 125I-brachytherapy for localized prostate cancer.
- To assess patient satisfaction with sexual function post-treatment.
- To determine the impact of neoadjuvant hormone therapy on EF recovery.
Main Methods:
- Prospective assessment of 131 sexually active patients with EF score >= 11 prior to treatment.
- Utilized the International Index of Erectile Function (IIEF) and Global Assessment Questionnaire (GAQ).
- Follow-up extended to at least 2 years, with sildenafil use permitted.
Main Results:
- Mean EF scores decreased within 3 months post-brachytherapy.
- EF scores recovered by the end of the first year and remained stable up to 2 years.
- 80% of patients reported satisfaction with sexual function up to 3 years post-treatment.
- Neoadjuvant hormone therapy did not significantly alter EF recovery patterns.
Conclusions:
- Permanent 125I-brachytherapy may cause temporary erectile dysfunction.
- Erectile function typically recovers within one year after treatment.
- Most patients achieve satisfactory sexual function and satisfaction post-brachytherapy.